Health Trials

About this trial

This multicenter, biomarker-driven, patient-centric study aimed to evaluate the efficacy of secondary cytoreduction followed by platinum-based chemotherapy in combination with anti-PD1/CTLA-4 bispecifics therapy in patients with platinum-sensitive relapsed ovarian cancer (PSROC).

Eligibility criteria

Qualifiers

Arm 1 (criteria-fulfilled, CF)

Age at recurrence ≥ 18 years, <80 years.

Patients with platinum-sensitive, first relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer (EOC, PPC, FTC), which is defined as those with treatment -free interval of 6 months or more.

If the patient had previous PARPi maintenance therapy, disease progression should occurring at lease 3 months after the prior PARPi withdrawal.

Disqualifiers

Patients with borderline, low-grade tumors, clear cell carcinoma, as well as non-epithelial tumors.

Patients with platinum-resistant or refractory diseases.

Lack of tumor samples (archived and/or recently obtained) for biomarker detection.

Previous administration of immunotherapy

Trial design

Treatments tested in this trial

  • surgery/chemotherapy
  • Iparomlimab/Tuvonralimab

Treatment groups

33 Participants
are divided into 3 treatment groups

Locations

2
Zhongshan Hospital Fudan University Shanghai China
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology Wuhan China

Sponsors and collaborators

Shanghai Gynecologic Oncology Group

Lead sponsor

Shanghai Zhongshan Hospital

Collaborator

Tongji Hospital

Collaborator

Source ClinicalTrials.gov